213 例镰状细胞病成年患者中 2019 冠状病毒病疫苗的安全性。
Safety of coronavirus disease 2019 vaccines in 213 adult patients with sickle cell disease.
机构信息
Department of Biotherapy, French National Sickle Cell Disease Referral Center, Hôpital Necker, Assistance-Publique Hôpitaux de Paris, Paris, France.
Laboratoire d'excellence sur le globule rouge GR-ex, Paris, France.
出版信息
Br J Haematol. 2023 Mar;200(5):563-567. doi: 10.1111/bjh.18547. Epub 2022 Nov 10.
Given the lack of information about safety of the COVID-19 vaccines for sickle cell disease (SCD) patients, we sought to determine whether COVID-19 vaccine was associated with subsequent hospital admission for vaso-occlusive events (VOEs). We included 402 patients with SCD, including 88 regularly transfused. As of July 31, 2021, 213 (53.0%) of them had received a least one dose of COVID vaccine (Pfizer 93.0%). We showed similar risk of hospital admission for a VOE among vaccinated patients (whether transfused or not) and among a control group of non-vaccinated patients matched for age, sex and genotype.
由于缺乏关于 COVID-19 疫苗在镰状细胞病（SCD）患者中的安全性信息，我们试图确定 COVID-19 疫苗是否与随后的血管阻塞性事件（VOE）住院有关。我们纳入了 402 名 SCD 患者，其中 88 名患者定期输血。截至 2021 年 7 月 31 日，其中 213 名（53.0%）患者至少接种了一剂 COVID 疫苗（辉瑞 93.0%）。我们发现，接种疫苗的患者（无论是否输血）和年龄、性别和基因型相匹配的未接种疫苗对照组患者的 VOE 住院风险相似。
Zotero 插件